As germline and tumor sequencing endeavors become incorporated into clinical cancer care, findings of missense variants, such as BRCA2 R3052W, with potentially uncertain functional consequences will be encountered more frequently (Thompson et al., 2001; Karchin et al., 2008; Guidugli et al., 2014). This evidence concerns the gene BRCA2 and neoplasm.